Search research articles
Contact Us
Filters
Showing results (251-260 of 479) with videos related to
Page
of 48
Sort By:
Molecular Cell
|
October 13, 2000
Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2
J Schwaller, E Parganas, D Wang, et al.
JCO Precision Oncology
|
November 9, 2023
Tretinoin Enhances the Effects of Chemotherapy in Juvenile Myelomonocytic Leukemia Using an Ex Vivo Drug Sensitivity Assay
Elliot Stieglitz, Christine J Gu, Michelle Richardson, et al.
Haematologica
|
February 25, 2021
The <i>EBF1-PDGFRB</i> T681I mutation is highly resistant to imatinib and dasatinib <i>in vitro</i> and detectable in clinical samples prior to treatment
Thai Hoa Tran, Jonathan V Nguyen, Adrian Stecula, et al.
Blood
|
November 15, 2007
Development of an allele-specific minimal residual disease assay for patients with juvenile myelomonocytic leukemia
Sophie Archambeault, Nikki J Flores, Ayami Yoshimi, et al.
Blood
|
October 26, 2016
Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia
Sarah K Tasian, David T Teachey, Yong Li, et al.
Cancer Discovery
|
June 13, 2024
Efficacy of the Allosteric MEK Inhibitor Trametinib in Relapsed and Refractory Juvenile Myelomonocytic Leukemia: a Report from the Children's Oncology Group
Elliot Stieglitz, Alex G Lee, Steven P Angus, et al.
Leukemia & Lymphoma
|
November 9, 2017
Severe pegaspargase hypersensitivity reaction rates (grade ≥3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children's oncology group (COG) clinical trials
Michael J Burke, Meenakshi Devidas, Kelly Maloney, et al.
Cancer Discovery
|
July 5, 2014
Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199
Triona Ni Chonghaile, Justine E Roderick, Cian Glenfield, et al.
Pediatric Blood & Cancer
|
June 1, 2023
Minimal residual disease predicts outcomes in KMT2A-rearranged but not KMT2A-germline infant acute lymphoblastic leukemia: Report from Children's Oncology Group study AALL0631
Kelly E Faulk, John A Kairalla, ZoAnn E Dreyer, et al.
Blood Advances
|
September 24, 2025
Age-based pegaspargase dosing is safe and achieves therapeutic levels in infants with ALL: report from COG AALL15P1
Kelly E Faulk, John A Kairalla, Emily Hibbitts, et al.
Page
of 48
Search research articles
Search
Showing results (251-260 of 479) with videos related to
Sort By:
Page
of 48
Molecular Cell
|
October 13, 2000
Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2
J Schwaller, E Parganas, D Wang, et al.
JCO Precision Oncology
|
November 9, 2023
Tretinoin Enhances the Effects of Chemotherapy in Juvenile Myelomonocytic Leukemia Using an Ex Vivo Drug Sensitivity Assay
Elliot Stieglitz, Christine J Gu, Michelle Richardson, et al.
Haematologica
|
February 25, 2021
The <i>EBF1-PDGFRB</i> T681I mutation is highly resistant to imatinib and dasatinib <i>in vitro</i> and detectable in clinical samples prior to treatment
Thai Hoa Tran, Jonathan V Nguyen, Adrian Stecula, et al.
Blood
|
November 15, 2007
Development of an allele-specific minimal residual disease assay for patients with juvenile myelomonocytic leukemia
Sophie Archambeault, Nikki J Flores, Ayami Yoshimi, et al.
Blood
|
October 26, 2016
Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia
Sarah K Tasian, David T Teachey, Yong Li, et al.
Cancer Discovery
|
June 13, 2024
Efficacy of the Allosteric MEK Inhibitor Trametinib in Relapsed and Refractory Juvenile Myelomonocytic Leukemia: a Report from the Children's Oncology Group
Elliot Stieglitz, Alex G Lee, Steven P Angus, et al.
Leukemia & Lymphoma
|
November 9, 2017
Severe pegaspargase hypersensitivity reaction rates (grade ≥3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children's oncology group (COG) clinical trials
Michael J Burke, Meenakshi Devidas, Kelly Maloney, et al.
Cancer Discovery
|
July 5, 2014
Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199
Triona Ni Chonghaile, Justine E Roderick, Cian Glenfield, et al.
Pediatric Blood & Cancer
|
June 1, 2023
Minimal residual disease predicts outcomes in KMT2A-rearranged but not KMT2A-germline infant acute lymphoblastic leukemia: Report from Children's Oncology Group study AALL0631
Kelly E Faulk, John A Kairalla, ZoAnn E Dreyer, et al.
Blood Advances
|
September 24, 2025
Age-based pegaspargase dosing is safe and achieves therapeutic levels in infants with ALL: report from COG AALL15P1
Kelly E Faulk, John A Kairalla, Emily Hibbitts, et al.
Page
of 48